These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20103549)

  • 21. Author's reply to Carracedo-Martínez E comment on: "prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in The Netherlands from 1998 to 2008".
    Stricker BH
    Drug Saf; 2014 Dec; 37(12):1071. PubMed ID: 25249048
    [No Abstract]   [Full Text] [Related]  

  • 22. Prescribing trend of pioglitazone after safety warning release in Korea.
    Jeong HE; Cho SI; Oh IS; Baek YH; Shin JY
    Am J Manag Care; 2019 Nov; 25(11):e342-e348. PubMed ID: 31747239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.
    Hurren KM; Taylor TN; Jaber LA
    Diabetes Res Clin Pract; 2011 Jul; 93(1):49-55. PubMed ID: 21440324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
    Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A cross-sectional analysis of the National Health and Nutrition Examination Survey.
    Gor D; Gerber BS; Walton SM; Lee TA; Nutescu EA; Touchette DR
    J Diabetes; 2020 May; 12(5):385-395. PubMed ID: 31652390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosiglitazone and cardiovascular risk.
    Brett AS
    N Engl J Med; 2007 Aug; 357(9):939; author reply 939-40. PubMed ID: 17806134
    [No Abstract]   [Full Text] [Related]  

  • 27. Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies.
    Noh Y; Kang DR; Kim DJ; Lee KJ; Lee S; Shin S
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1338-1346. PubMed ID: 28771933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
    Doggrell SA
    Expert Opin Pharmacother; 2008 Feb; 9(3):405-20. PubMed ID: 18220491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
    Odom J; Williamson B; Carter L
    Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
    [No Abstract]   [Full Text] [Related]  

  • 30. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. National trends in the use of antibiotics by primary care physicians for adult patients with cough.
    Metlay JP; Stafford RS; Singer DE
    Arch Intern Med; 1998 Sep; 158(16):1813-8. PubMed ID: 9738612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initiating antidiabetic drug therapy.
    Kostenbauder HB
    Clin Ther; 2008 May; 30(5):986; author reply 986-7. PubMed ID: 18555946
    [No Abstract]   [Full Text] [Related]  

  • 33. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg et al.
    Brunzell JD
    Diabetes Care; 2005 Dec; 28(12):2984-5; author reply 2985-6. PubMed ID: 16331869
    [No Abstract]   [Full Text] [Related]  

  • 34. Trends in antimicrobial prescribing rates for children and adolescents.
    McCaig LF; Besser RE; Hughes JM
    JAMA; 2002 Jun; 287(23):3096-102. PubMed ID: 12069672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002.
    Stafford RS; Furberg CD; Finkelstein SN; Cockburn IM; Alehegn T; Ma J
    JAMA; 2004 Jan; 291(1):54-62. PubMed ID: 14709576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value equation for rosiglitazone and pioglitazone in older persons.
    Zarowitz BJ
    Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
    [No Abstract]   [Full Text] [Related]  

  • 38. National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017.
    Su ZT; Segal JB; Lanzkron S; Ogunsile FJ
    Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1246-1250. PubMed ID: 31328369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013.
    Clemens KK; Liu K; Shariff S; Schernthaner G; Tangri N; Garg AX
    Diabetes Obes Metab; 2016 Jun; 18(6):607-14. PubMed ID: 26939711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glitazones and the cardiovascular system.
    Devchand PR
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):188-92. PubMed ID: 18316956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.